Latest Share Chat

REMOVE ADS

Proteome Regulatory News (PRM)

Proteome Information

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes

Get Live Data

1.55 0.00 (0.00%)

Bid:

1.56

Ask:

1.99

Spread: 0.43 (27.564%)

Market Cap: £5.44m

Last checked at -

Intraday Proteome Share Chart

REMOVE ADS

Investor Presentation

1 Apr 2021 09:34

RNS Number : 2927U

Proteome Sciences PLC

01 April 2021

REACH: non-regulatory announcement

1 April 2021

PROTEOME SCIENCES PLC

("Proteome Sciences", "the Group", or "the Company")

Investor Presentation

Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company's results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and select to meet Proteome Sciences PLC via: https://www.investormeetcompany.com/proteome-sciences-plc/register-investor

Investors who already follow Proteome Sciences PLC on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Proteome Sciences plc
Mariola Soehngen M.D., Chief Executive Officer Dr Ian Pike, Chief Scientific Officer	Tel: +44 (0)20 7043 2116
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter - Corporate Finance Tony Quirke - Sales and Corporate Broking	Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUUWCUPGURG

Date		Source	Headline
8th Oct 2007	2:34 pm	PRN	Statement regarding mailing of interim report
2nd Oct 2007	4:28 pm	PRN	Directorate Change
28th Sep 2007	8:00 am	PRN	Interim Results
21st Sep 2007	9:54 am	PRN	Press Release re Intronn Inc.
6th Sep 2007	4:27 pm	PRN	Notifiable Interest
17th Aug 2007	6:15 pm	PRN	AIM Rule 26 & Adviser Name
30th Jul 2007	7:00 am	PRN	Statement re US Patent Allowed
25th Jul 2007	12:03 pm	PRN	Director's Dealing
12th Jul 2007	2:58 pm	PRN	Notifiable Interest
2nd Jul 2007	4:59 pm	PRN	Director/PDMR Shareholding
29th Jun 2007	8:15 am	PRN	Further Loan Agreement
29th Jun 2007	8:00 am	PRN	Final Results
22nd May 2007	3:50 pm	PRN	Notifiable Interest
15th May 2007	11:38 am	PRN	Grant of European Patent
14th May 2007	11:40 am	PRN	Notifiable Interest
10th May 2007	5:03 pm	PRN	Notifiable Interest
8th May 2007	8:30 am	PRN	Notice of Allowance of TMT1 Patent in Canada
25th Apr 2007	3:32 pm	PRN	Blocklisting - Interim Review
20th Apr 2007	11:03 am	PRN	Director's Dealings
19th Apr 2007	2:26 pm	PRN	Notifiable Interest
18th Apr 2007	8:30 am	PRN	Service Agreement with Onconome Inc.
13th Apr 2007	12:20 pm	PRN	Notifiable Interest
13th Apr 2007	12:13 pm	PRN	Notifiable Interest
21st Mar 2007	7:00 am	PRN	Holding(s) in Company
21st Mar 2007	7:00 am	PRN	Holding(s) in Company
21st Mar 2007	7:00 am	PRN	Holding(s) in Company
21st Feb 2007	9:41 am	PRN	Press Release
19th Feb 2007	4:40 pm	PRN	Holding(s) in Company
15th Jan 2007	7:00 am	PRN	Statement re Issuance of Patent
5th Jan 2007	12:29 pm	PRN	Holding(s) in Company
21st Dec 2006	4:59 pm	PRN	Holding(s) in Company
18th Dec 2006	2:12 pm	PRN	Statement re: Patent
13th Dec 2006	2:07 pm	PRN	Statement re Issuance of Patent
13th Dec 2006	11:32 am	PRN	Total Voting Rights
11th Dec 2006	10:49 am	PRN	Statement re: Issuance of Patent
31st Oct 2006	12:42 pm	PRN	Holding(s) in Company
30th Oct 2006	5:38 pm	PRN	Blocklisting
5th Sep 2006	9:54 am	PRN	Directorate Change
27th Jul 2006	1:53 pm	PRN	Holding(s) in Company
27th Jul 2006	12:04 pm	PRN	Result of AGM
18th Jul 2006	7:00 am	PRN	Appointment
17th Jul 2006	4:41 pm	RNS	Second Price Monitoring Extn
17th Jul 2006	4:36 pm	RNS	Price Monitoring Extension
6th Jul 2006	5:12 pm	PRN	Holding(s) in Company
4th Jul 2006	4:42 pm	RNS	Second Price Monitoring Extn
4th Jul 2006	4:36 pm	RNS	Price Monitoring Extension
29th Jun 2006	2:00 pm	PRN	Final Results
28th Jun 2006	4:42 pm	RNS	Second Price Monitoring Extn
28th Jun 2006	4:36 pm	RNS	Price Monitoring Extension
28th Jun 2006	4:32 pm	PRN	Re Licence Agreement

Latest Share Chat

Proteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Intraday Proteome Share Chart

Investor Presentation

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending